Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Participants who met the following main selection criteria were included in the study.~Inclusion Criteria:~* Histologically or cytologically proven adenocarcinoma of the colon or rectum~* Metastatic disease that is not amenable to potentially curative treatment~* One and only one prior line of treatment for metastatic disease. This prior line should be an oxaliplatin based chemotherapy (participants who relapse within 6 months of completion of oxaliplatin based adjuvant chemotherapy are eligible)~* Prior treatment with bevacizumab is permitted.~Exclusion Criteria:~* Prior therapy with irinotecan~* Eastern Cooperative Oncology Group performance status \>2~The above information is not intended to contain all considerations relevant to participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/FOLFIRI (Type: PLACEBO_COMPARATOR): Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
- Aflibercept/FOLFIRI (Type: EXPERIMENTAL): Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met

Based on this trial design, predict the completion outcome and termination type (if applicable).